Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vigil Neuroscience, Inc. - Common Stock
(NQ:
VIGL
)
3.490
+0.030 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vigil Neuroscience, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024
August 13, 2024
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
August 01, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
July 30, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
July 24, 2024
Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support...
Via
Benzinga
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
July 24, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
July 18, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
July 18, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
June 27, 2024
Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP.
Via
InvestorPlace
Why Is Branchout Food (BOF) Stock Down 39% Today?
June 27, 2024
Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each.
Via
InvestorPlace
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
June 27, 2024
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 27, 2024
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Via
InvestorPlace
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
June 27, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 12, 2024
Via
Benzinga
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
June 11, 2024
Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments.
Via
InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
June 11, 2024
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Via
InvestorPlace
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 08, 2024
Via
Benzinga
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
May 07, 2024
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
March 26, 2024
VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to...
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.